Designing a patent family strategy in life sciences requires more than prosecution. This article explains how U.S. continuation practice can be structured as patent family architecture, aligned to biotech and pharmaceutical regulatory milestones, valuation strategy, licensing, and commercialization, while strengthening patent portfolio risk mitigation.